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Abstract
Bacteria can acquire resistance against antibiotics by covalently modifying them. This is achieved
by plasmid-encoded enzymes called as aminoglycoside modifying enzymes (AGMEs). More than
50 different AGMEs are known currently, having variable levels of substrate promiscuity. Even
though these enzymes are highly similar on the sequence level and also share a similar structural
fold, the molecular basis of promiscuity is not clearly understood. We aim to characterize enzymes
with high and low substrate promiscuity and compare their properties to better understand ligand
selectivity of AGMEs.
This project describes the kinetic, thermodynamic and structural properties of aminoglycoside N3
acetyltransferase VIa (AAC-VIa). It is one of the least promiscuous AGMEs, being able to modify
only five aminoglycosides. Unlike the more promiscuous aminoglycoside N3-acetyltransferase
IIIb (AAC-IIIb), AAC-VIa can kinetically distinguish between its various substrates.
Thermodynamic studies determined the binding of ligands to be enthalpically driven and
entropically unfavorable. Unlike other AGMEs, the formation of binary and ternary complexes
was accompanied by a net deprotonation of the enzyme, ligand or both. Analytical
ultracentrifugation (AUC) studies showed that AAC-VIa exists in a monomer-dimer equilibrium,
with more dimeric form appearing with increasing concentrations of the enzyme. Binding of
ligands drive the enzyme to the monomeric form. Also, dimer formation, unlike the AAC-IIIb,
was observed to be achieved through polar interactions. X-ray crystallography using the apo- and
ligand bound forms of AAC-VIa was performed to decipher the catalytic mechanism of
acetylation. Crystal structures of different complexes of the enzyme showed that structures of apo-
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and ligand-bound forms are similar which suggests that, unlike other AGMEs, more rigid structure
of AAC-VIa may limit the active site to accommodate only few selected aminoglycosides, hence
low substrate promiscuity. The structures also suggested a novel catalytic mechanism involving a
non-classical catalytic triad. Neutron diffraction studies were used to identify a low barrier
hydrogen bond between the active site residues. Overall, we highlight the contrasting properties
of the high and low substrate promiscuous acetyltransferases, while also being the first one to
report the unique mechanism of acetyl transfer. Results from this work can aid the development of
next generation of aminoglycoside drugs.
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CHAPTER I
INTRODUCTION
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Aminoglycoside antibiotics are a group of clinically important broad-spectrum bactericidal agents.
Streptomycin was the first aminoglycoside to be isolated from Streptomyces griseus, by Waksman
in 1944 and was used to treat tuberculosis[1]. This was followed by the discovery of neomycin
[2], kanamycin [3] tobramycin [4], sisomicin [5] gentamicin [6]. These drugs have long been used
to treat bacterial infections caused by Gram-positive and Gram-negative bacteria, including
tuberculosis, meningitis, listeriosis and nosocomial infections. Several semi-synthetic
aminoglycosides like dibekacin, amikacin [7] and netilmicin were later developed in the 1970s to
help target the bacterial strains that had developed resistance, although not all of them were
successful. Additionally, there also have been attempts to develop new aminoglycosides by
chemically modifying the available aminoglycosides to evade the bacterial resistant enzymes [8].
Structurally aminoglycosides are composed of an aminocyclitol moiety with aminated sugar
substituents. The most common moiety is 2-deoxystreptamine (2-DOS), which is found in most
clinically important aminoglycosides, although it can also be streptamine or streptidine (Park et al
2013). The 2-DOS containing aminoglycosides are grouped into two major classes, depending on
the substitution patterns of sugars (Figure 1.1).
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Figure 1.1 Representative aminoglycoside structures. Structures of the 2-deoxystreptamine ring
containing aminoglycosides. The left panel shows 4,6-disubstituted kanamycins, with the
structures of sisomicin, kanamycin A and kanamycin B shown. The 4,5-disubstituted neomycins
are on the right, structures of ribostamycin, neomycin and paromomycin shown at the bottom.

The 4,5-disubstituted aminoglycosides belong to the neomycin class, whereas the 4,6-disubstituted
aminoglycosides fall in the kanamycin class. Antibiotic activity depends little on the hydroxyl
groups, but the number and positions of amino groups play an important role in antibiotic activity.
Aminoglycosides belonging to the kanamycin class are used to treat serious opportunistic
infections caused by Gram-negative bacteria and neomycin class aminoglycosides are typically
used for topical application and intestinal parasites [9-11]. Aminoglycosides have also been used
as a component of multidrug therapies to treat diseases like tuberculosis [12], where pathogenic
bacterial strains have turned resistant against several drugs.
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The bactericidal action of aminoglycosides is primarily due to their association with bacterial
ribosomes. They exert their effects by associating with the 16S rRNA subunit of the bacterial
ribosome [13, 14]. Based on the structural complementarity between the aminoglycoside and the
binding site on the 16S rRNA, different aminoglycosides bind to different sites [15]. They interfere
with the recognition of cognate tRNA by rRNA, causing misreading of the codon[16]. Binding of
aminoglycoside can also hinder the elongation of the polypeptide chain by disrupting the
translocation of tRNA from A-site to the P-site and may also cause premature termination[17].
The accumulation of aberrant proteins in the cell might be followed by their insertion into the cell
membrane, altering its permeability and allowing the entry of more aminoglycoside molecules in
the cell, eventually leading to cell death [18, 19].
Despite being clinically useful for several years, the use of aminoglycosides has drastically
decreased over the years. This reduction in the usage has been primarily due to the emergence of
resistance in pathogenic bacteria, but also because of their clinical side effects, which include renal
toxicity and ototoxicity [20, 21]. Aminoglycosides have been shown to non-specifically interact
with nucleic acids and eukaryotic ribosomes and can inhibit protein synthesis at higher
concentrations [22].
However, development of resistance remains the primary cause for the significant decrease in the
effectiveness of aminoglycosides[23]. Antibiotic resistance has become a global health crisis,
resulting in a substantial clinical and economic burdens on health care systems worldwide.
Resistance can be achieved by multiple mechanisms. These include modification of target
ribosome binding sites and reduction in drug uptake. Bacteria can reduce the amount of
aminoglycoside entering the cell by altering membrane proteins and actively effluxing the drug
4

out [24]. However, the most prevalent resistance mechanism is the enzymatic covalent
modification of the drugs. This is achieved by enzymes known as aminoglycoside modifying
enzymes (AGMEs) that are easily spread among bacterial populations through horizontal gene
transfer of resistance plasmids encoding for these enzymes. These enzymes can covalently modify
their substrates, rendering them ineffective against pathogenic bacteria [25]. Resistance enzymes
are expressed in high concentrations and some have been shown to operate at the diffusion limit.
More than 50 different AGMEs are known currently, categorized into three different families,
based on the type of modification carried out. These modifications are phosphorylation,
nucleotidylation and acetylation. Aminoglycoside phosphotransferases (APHs) transfer the
terminal phosphate group from ATP to a hydroxyl group on the aminoglycoside and have evolved
from protein kinases [26]. Aminoglycoside nucleotidyltransferases (ANTs) belong to the
polymerase superfamily which includes DNA and RNA polymerases and transfer the adenosine
monophosphate from ATP to a hydroxyl group on the antibiotic [27]. Aminoglycoside
acetyltransferases (AACs) were the first AGMEs to be reported and are the most commonly found
in clinical isolates of resistant strains. AACs were also the first identified members of the GCN5
related N acetyltransferase (GNAT) superfamily of enzymes [28]. Enzymes belonging to the
GNAT superfamily are universally distributed in nature and catalyze the transfer of an acetyl group
from acyl CoAs to a primary amine group on diverse acyl-accepting substrates [29]. This
superfamily includes histone acetyltransferases (HATs), serotonin-N-acetyltransferases (SNATs),
also known as arylalkylamine N-acetyltransferases (AANATs), and glucosamine-6-phosphate Nacetyltransferases.
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These covalent modifications carried out by AGMEs drastically reduce the ability of the antibiotics
to bind their target. For instance, acetylation of aminoglycosides reduces the affinity of
aminoglycosides for the acceptor tRNA site on the 30S ribosome by 4 orders of magnitude [30].
Also, any particular aminoglycoside can be modified by several different aminoglycoside
modifying enzymes (AGMEs) (Figure 1.2). Aminoglycoside modifying enzymes display a range
of substrate promiscuity, some of them are highly promiscuous and can modify more than a dozen
aminoglycoside antibiotics, whereas others are limited to modifying only a few
aminoglycosides.The reason behind this substrate promiscuity and the underlying mechanism
remains largely unknown. Moreover, no correlation has been confirmatively observed between the
sequence or structure of an AGME and its substrate profile.

Figure 1.2 Modifications by AGMEs. Structure of kanamycin B showing the sites of
modification by aminoglycoside acetyltrasferases, phophotransferases and nucleotidyltransferases
[15].
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Our laboratory’s goal is to understand the molecular principles underlying this ligand selectivity
by deciphering the thermodynamic, structural and dynamic properties of enzyme-ligand
complexes.
Like AGMEs, other proteins such as cytochrome P450s, multidrug resistance (MDR) transporters
and MDR transporter transcription activators also demonstrate high substrate promiscuity[31]. A
variety of different features have been observed to be responsible for the ligand selectivity
exhibited by these enzymes. Some of these include spacious and hydrophobic active sites, active
site restructuring and changes in protein dynamics [32]. Chen et al. used extensive structural
studies to propose a basis for the broad substrate specificity of aromatic prenyltransferases. These
enzymes harbor a large hydrophobic pocket, which is able to accommodate a wide range of
substrates. Also, the different substrates can bind in different orientations, resulting in catalysis
with

different

binding

affinities

and

efficiencies[33].Fructose-1.6-bisphosphate

aldolase/phosphatase is able to catalyze two different chemical reactions, an aldol condensation
and dephosphorylation reaction using the same active site by rearranging the loops within its active
site [34].
Increased conformational flexibility has been proposed to be the underlying cause of substrate
promiscuity displayed by enzymes like cytochrome P450s [35]. A more flexible protein can
explore greater conformational space due to its intrinsic dynamics, making it possible to bind
different ligands, as has been observed in the case of PDZ domains [36] . Conformational
fluctuations were also found to be the underlying cause of the promiscuity displayed by another
group of bacterial resistance enzymes, β-lactamases. Zou et al. proposed that beta-lactamases have
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evolved from being promiscuous generalist enzymes to substrate specific specialist enzymes by
mutations which change the dynamics, leading to changes in the substrate specificity of the
enzymes [37].
AGMEs have also been demonstrated to employ a few of these features to exhibit different
substrate profiles. Aminoglycoside phosphotransferase (3’)-IIIa (APH (3’)-IIIa), is one of the most
promiscuous AGMEs and is able to catalyze aminoglycosides from both the kanamycin as well as
neomycin class. It accomplishes this by having three different subsites within its active site, which
allows the binding of structurally different substrate components. It also has a flexible loop, which
forms differential interactions with different substrates [31]. Conformational dynamics has also
been shown to be responsible for the high substrate promiscuity of another aminoglycoside N3
acetyltransferase, AAC-IIIb. Similar to APH(3’)-IIIa, AAC-IIIb is highly promiscuous and is
capable of modifying upto 15 structurally different aminoglycosides, from the neomycin and the
kanamycin classes [38] . Binding of CoASH, a substrate analog, induces conformational changes
in the flexible loop of the protein, making it more flexible and aiding the binding of structurally
different substrates [39]. Differences in solvent rearrangement has also been proposed to play a
role in the broad substrate specificity demonstrated by AGMEs like APH(3’)-IIIa and AAC-IIIb
[40].
In this work, I have described the cloning, over expression and purification of the aminoglycoside
N3 acetyltransferase-VIa (AAC-VIa) followed by its kinetic, thermodynamic and structural
characterization. AAC-VIa catalyzes the modification of N3 atom of the 2-DOS ring on
aminoglycosides by transferring an acetyl group from acetyl CoA. Despite significant sequence
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similarity to other aminoglycoside acetyltransferases, unlike others, it has a very limited substrate
profile. We have previously obtained thermodynamic and structural data for the highly and
moderately promiscuous aminoglycoside acetyltransferases. Characterizing AAC-VIa presents an
excellent opportunity to study molecular basis of ligand promiscuity because it catalyzes the exact
same reaction as other acetyltransferase but has a very limited substrate profile.
AAC-VIa was initially detected mainly in Escherichia coli (E.coli) and other Gram negative
clinical isolates. The gene encoding the protein was later cloned from a clinical isolate of
aminoglycoside resistant strain of Enterobacter cloacae. The resistance profile was determined by
minimum inhibitory concentration (MIC) assays. Modification of aminoglycoside substrates was
determined by HPLC isolation of acetylated aminoglycoside products. It was determined that
AAC-VIa confers high-level resistance to gentamicin and sisomicin and moderate level resistance
to tobramycin and netilmicin. Further biochemical characterization of AAC-VIa has been not
performed in the earlier studies [41].
To characterize AAC-VIa, a protocol maximizing the overexpression of the protein in soluble form
was developed and optimized. A protocol for purification of AAC-VIa was also devised and
optimized resulting in >95% pure protein, followed by a kinetic and thermodynamic
characterization. AAC-VIa was found to behave similarly to some of the previously characterized
more promiscuous AGMEs in certain thermodynamic aspects, and yet exhibits quite different
kinetic and oligomerization properties.
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Next structural determination of AAC-VIa was undertaken to gain a better understanding of the
catalytic mechanism, since many aminoglycoside acetyltransferases have been crystallized and
kinetic and catalytic mechanism details have been reported for a few, but a complete structural and
mechanistic picture is lacking for most of them. This work was performed in collaboration with
Dr. Matthew J. Cuneo, at the Center for Structural Molecular Biology, Oak Ridge National
Laboratory.
Crystal structures of the following AACs are available in the PDB, AAC(2’)-Ic [42], AAC(6’)-Iy
[43] AAC(6’)-Ii [44], AAC(6’)-Ie [45], AAC(6’)-Ib [46, 47], AAC(6’)-Ig and AAC(6’)-Ih
[48],AAC(3)-Ia [49], AAC(3)-Ib (PDB ID:4YFJ). The general mechanism of acetylation involves
the direct nucleophilic attack of the amine group to be acetylated on the carbonyl carbon of the
acetyl CoA. A tetrahedral intermediate is thus formed, followed by the protonation of the thiolate
anion and subsequent release of the products [28].All AACs studied to date exhibit a sequential
kinetic mechanism, requiring both substrates to be bound before catalysis. Acetyl CoA is the first
substrate to bind, followed by the aminoglycoside. [42, 43, 50, 51]. Across AACs, various residues
have been reported to be involved in activating the amine group for the nucleophilic attack by
acting as a general base, in the stabilization of the tetrahedral intermediate and the protonation of
the thiolate anion and product release. For instance, residues like glutamate, tryptophan [42] and
aspartate[47] have been postulated to function as remote base, whereas tyrosine has been
hypothesized to act as a general acid to protonate the CoA thiolate anion [42, 47]. In several cases,
water molecules can also mediate protonation of the leaving thiolate anion [43]. Valine, asparagine
and leucine are involved in stabilization of the transition state [42, 47, 52].

10

Thus, amongst the AACs that have been characterized so far, there has been no conservation of
the active site machinery or the catalytically important residues. Additionally, there has been no
report of a catalytic triad responsible for the acetylation activity of any of the AACs studied.
Interestingly, the presence of a catalytic triad has been reported to be essential to the activity of
arylamine-N-acetyltransferases (NATs), which are not a part of the GNAT superfamily [53].
NATs catalyze the acetylation of arylamines and arylhydrazines using a catalytic triad, consisting
of Cys-His-Asp, which was thought to be strictly conserved until the enzyme (BACCR) NAT3
was characterized. This enzyme isolated from Bacillus cereus possesses an atypical Cys-His-Glu
[54]. In contrast to other members of this family, the change from Asp to Glu did not affect the
enzyme’s structure and function, indicating that the catalytic triad of these acetyltransferases is
plastic. Notably, all of the AACs characterized so far confer resistance against a broad spectrum
of aminoglycoside antibiotics. No crystal structures have been reported for an AAC exhibiting
limited substrate profile such as AAC-VIa.
The crystal structures of AAC-VIa were successfully determined in six different complexes in high
resolution, ranging from 1.8-2.2 angstroms. This represents the first report of the structures of all
catalytically important complexes for a single aminoglycoside acetyltransferase. Also, we
demonstrated that the crystallized enzyme is capable of performing catalysis, indicating that the
crystalline form is a biologically relevant form of the enzyme. We were also able to capture the
enzyme bound to the acetylated drug, which is one of the products of the reaction, the first ever
crystal structure of its kind to be reported for an aminoglycoside acetyltransferase. Our
crystallization studies support a previously unidentified novel catalytic mechanism, involving a
non-classical catalytic triad in the active site of the enzyme. This unconventional triad consists of
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a His and a Glu residue, with the aminoglycoside substrate being a part of the triad.We also
observed that the catalytic process involves the protonated states of the active site residues, which
was successfully demonstrated by neutron diffraction studies. Along with AAC-VIa, we have also
solved crystal structures of the more promiscuous AAC-IIIb, which also has a similar active site
and catalytic mechanism as AAC-VIa.
Overall, these studies will provide a better understanding of the principles underlying ligand
promiscuity. In addition, the results from this work would also contribute to knowledge about
protein-small molecule interactions, and can possibly be useful in the development of more
effective drugs against pathogenic bacteria.
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CHAPTER II
CLONING, EXPRESSION AND PURIFICATION OF AMINOGLYCOSIDE N3
ACETYLTRANSFERASE VIa

13

2.1 Abstract
AAC-VIa is an AGME with lower substrate promiscuity relative to other AGMEs, and can modify
only five different aminoglycosides. The AAC-VIa was isolated from a clinical isolate of
Enterobacter cloacae. The gene was cloned into a cloning vector TOPO2.1 and eventually
subcloned into a protein expression vector, pET15b and transformed into E.coli BL21DE3.
Overexpression conditions were optimized to maximize the soluble form of the protein. The
purification protocol was also modified to obtain >95% pure protein. Initial characterization of the
enzyme included coupled enzyme assays to determine the substrate profile, DSC to determine the
reversibility of thermal denaturation and CD to determine if the protein is folded.
2.2 Introduction
AAC-VIa is one of the 14 enzymes that show highly variable substrate profiles and catalyze the
same reaction which is the modification of N3 atom of the 2-deoxystreptamine (2-DOS) ring on
aminoglycosides by transfer of an acetyl group from acetyl CoA[41]. Despite its >55% sequence
similarity to the aminoglycoside N3 acetyltransferase-IIIb (AAC-IIIb), an acetyltransferase with
high substrate promiscuity, AAC-VIa, unlike AAC-IIIb, is unable to modify neomycins, and its
substrate profile is limited to gentamicin (C1 and C2), sisomicin, tobramycin and kanamycin B. It
also shows similar sequence homology to another acetyltransferase (AAC-IVa) having a highly
limited substrate profile, but gentamicin is the only common substrate between them.
A lot of highly promiscuous enzymes have been characterized kinetically, thermodynamically and
structurally, but information about the lesser promiscuous ones is still lacking. This works involves
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the characterization of AAC-VIa, an acetyltransferase with low substrate promiscuity. This chapter
describes the cloning of the gene encoding AAC-VIa, followed by the optimization of the protein’s
overexpression and purification.
2.3 Materials and Methods
2.3.1 Materials
TOPO TA cloning kit was purchased from Thermo Fisher Scientific (Waltham, MA). E.coli BL21
(DE3) and pET15b were purchased from Novagen (Madison, WI). Tryptone, yeast extract and
sodium chloride were purchased from Fisher Scientific (Waltham, MA). All restriction enzymes
were purchased from New England Biolabs (Ipswich, MA). Isopropylthiogalactopyranoside
(IPTG) was purchased from Inalco Pharmaceuticals (Milan, Italy). High-performance NiSepharose was purchased from GE Healthcare (Alpharetta, GA) and ion-exchange matrix (Macro
Q) was purchased from Bio-Rad Laboratories (Hercules, CA). Purified thrombin was obtained
from Enzyme Research (South Bend, IN). All aminoglycosides, coenzymes and reagents of the
highest possible purity were purchased from Sigma (St. Louis, MO). Aminoglycosides are
purchased as sulfate salts and were used in the base form after the removal of sulfate ion by ion
exchange chromatography.
2.3.2 Cloning of AAC-VIa
Genomic DNA from Enterobacter cloacae was isolated by Dr. Gladys Alexandre. The gene
encoding AAC-VIa is 900bp long. The protein consists of 299 amino acid residues. The desired
gene was obtained by PCR amplification using gene-specific primers, flanked by restriction
enzyme sites, NdeI (for forward primer) and Bam HI (for reverse primer).
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The sequences for the primers were as follows:
Forward primer: 5’ CAT ATG ACT GAT CCC CGC AAA AAC GGC
Reverse primer: 5’ GGA TTC TCA GTC GCG GCG TTG TTT
The following thermal cycles were used for PCR amplification: hotstart at 95°C for 3 minutes,
denaturation at 95°C for 2 minutes, annealing at 58°C for 45 seconds, extension at 72°C for 1
minute, final extension at 72°C for 5 minutes. The denaturation, annealing and extension were
performed for 35 cycles.
1% agarose gel electrophoresis was used to confirm the right length of the amplified segment.
Thus obtained PCR product was then cloned into TOPO 2.1 vector by TA cloning, followed by
ligation and transformation into E. coli TOP10 competent cells. Positive colonies were selected by
blue/white screening, followed by plasmid isolation and confirmation of the positive clone by
sequencing. Subcloning into a protein expression vector, pET-15b was performed by first digesting
the TOPO vector using the NdeI and Bam HI restriction endonucleases and then ligating the insert
into the pET-15b vector. The recombinant plasmid was again confirmed by sequencing and
subsequently transformed into E.coli BL21 DE3 competent cells for protein expression.
2.3.3 Optimization of conditions for protein expression
For protein expression, 5ml of overnight grown culture of E. coli BL21DE3 cells was used as an
inoculum for 500ml of LB medium (containing 100μg/ml Ampicillin) and grown at 37°C, 200
rpm. Once the O.D 600 reached 0.6-0.8, the cultures were induced for protein expression by IPTG.
Two different concentrations of IPTG were used for induction of protein expression, 0.5mM and
1mM. Post-induction, cultures were incubated at 37°C, 200 rpm and samples were collected every
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hour until 5 hours. SDS-PAGE electrophoresis was performed using samples from different timepoints to monitor protein overexpression.
To determine whether the protein is being expressed in the soluble or insoluble fraction, cells were
grown for 3.5 hours, after induction using 0.5mM and 1mM IPTG and harvested by centrifuging
at 6000rpm for 20 min. The resultant cell pellet was resuspended in lysis buffer (50mM Tris,
100mM NaCl,20mM imidazole and 100mM PMSF, pH=7.6) and lysed by three passes through
French Press. This was followed by centrifugation at 17,000 rpm at 4°C for 1 hour to separate the
soluble and the insoluble fractions. All samples were loaded onto SDS-PAGE to observe the
relative overexpression of protein in the two fractions.
2.3.4 Optimization of protein purification
Determining suitable concentration of imidazole for elution of His-tagged protein.
Cells were resuspended in lysis buffer, lysed by three rounds through a French Press, followed by
centrifugation at 17,000 rpm at 4°C for 1 hour to separate the insoluble and soluble fractions. Thus
obtained supernatant was passed through Ni2+ -NTA column. Elution was performed using
imidazole. To determine an appropriate concentration of imidazole for elution, a gradient from
20mM to 500mM imidazole was used and 2ml fractions were collected. Protein concentration was
checked for each fraction by recording absorbance at 280nm.
Determining conditions for efficient thrombin cleavage.
The optimum conditions for thrombin cleavage were determined by varying different conditions
including pH, duration of incubation and temperature. The protein sample was incubated with
thrombin, for four hours at room temperature and for overnight at 4 degrees, at two different pHs
7.6 and 8.0.
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Determining conditions for anion exchange chromatography.
Salt gradient and pH for elution were optimized. Elution was performed using salt gradient of
50mM Tris, 100mM to 2M NaCl, and 50mM Tris, 0-1M NaCl, over two column volumes at pHs
of 7.6 and 8.0.
2.3.5 Steady state kinetics
Kinetic parameters for AAC-VIa activity were determined using Cary-Win UV-Vis
spectrophotometer (Varian, Palo Alto, CA). The formation of product was measured by an increase
in the absorbance of pyridine-4-thiolate at 324 nm as previously described [55-57]. Assay mixtures
consisted of 50mM Tris-Cl, 100mM NaCl (pH=7.6 at 25˚C) and AAC-VIa (10nM). The reaction
was initiated by addition of aminoglycoside at various concentrations while the concentration of
acetyl CoA was kept constant at saturating level of 100μM. Reaction with all the substrates
followed Michaelis-Menten type kinetics.
2.3.6 Circular dichroism spectroscopy
CD experiments were performed on an Aviv CD spectrophotometer in a 1mm cuvette. 5μM
enzyme was used for all the scans and 99% saturation was used for all the ligands. Wavelength
scans were collected at 25°C, from 260-190nm, at a scan rate of 1.0nm/min. Average for 4 scans
were collected. Buffer scan was collected and was subtracted from the protein sample’s scan,
followed by the calculation of molar ellipticity. Temperature scans were performed at 222nm in
the range of 25-80°C, equilibration time at each temperature being 1 minute, with a deadband of
0.05 degrees.
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2.4 Results
2.4.1 Cloning and optimization of protein overexpression conditions
The gene encoding the AAC-VIa was successfully cloned into an expression vector and
transformed into E.coli BL21DE3 cells. Induction with 0.5mM IPTG followed by incubation for
3.5 hours was found to be suitable for sufficient protein expression in the soluble fraction. (Figures
2.1 and 2.2)

Figure 2.1 AAC-VIa overexpression. Lane 1 shows the protein standards marker, cultures
induced with 0.5mM IPTG, hourly timepoints from 0-5 hours (lanes 2-7), induced with 1mM IPTG
(lanes 9-14).
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Figure 2.2 SDS-PAGE to determine overexpression of AAC-VIa in soluble (supernatant) and
insoluble (pellet) fractions. Lane 1 shows protein standard marker, cell lysate pellet for cultures
induced with 0.5mM IPTG (lanes 2 and 3) and 1mM IPTG (lanes 4 and 5), supernatant from
cultures induced with 1mM IPTG (lanes 8 and 9).

2.4.2 Optimization of protein purification
Determining suitable concentration of imidazole for elution of His-tagged protein.
To elute the His-tagged AAC-VIa from Ni2+-NTA column, a gradient elution was performed using
20mM to 500mM imidazole and 2ml fractions were collected. Absorbance at 280nm was checked
to determine the protein concentration in all the fractions. It was found that 300mM imidazole was
sufficient to elute all the protein from the column (Figure 2.3).
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Figure 2.3 AAC-VIa fractions eluted from Ni-NTA column. AAC-IIIb; 28.9 kDa (lane 1) and
APH (3’)-IIIa; 30 kDa (lane 2) were used as controls for the molecular weight. Cell lysate
supernatant and pellet (lane 1 and 2), fractions from the Ni-NTA column, flowthrough, wash and
eluted AAC-VIa protein (~32 kDa).

Determining conditions for efficient thrombin cleavage. Thrombin is a protease which cleaves the
peptide bond between Arg and Gly, in the sequence: Leu-Val-Pro-Arg-Gly-Ser, thus removing the
His tag from the protein. To determine the conditions for the most efficient thrombin cleavage,
different periods of incubation were tested. Two different pHs, 7.6 and 8.0 and temperatures, 4˚C
and 25˚C were tried. The most efficient cleavage was observed when performed at room
temperature for 4 hours at a pH of 8.0.
Determining conditions for anion exchange chromatography. Anion exchange chromatography
was used to remove the thrombin from AAC-VIa, post-thrombin cleavage. Salt gradient from 0M1M NaCl, at a pH of 8.0 provided the best separation of AAC-VIa from thrombin (Figure 2.4).
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Figure 2.4 AAC-VIa fractions eluted from anion exchange chromatography column. APH
(3’)-IIIa; 30 kDa (lane 1) was used as control for the molecular weight. Fractions from the Macro
Q column, flowthrough (lane 2), elution fractions containing AAC-VIa protein (lanes 3-5). Old
AAC-VIa (~32 kDa) was used as a control (lane 6).

2.4.3 Steady state kinetics
Substrate profile was found to be limited to only five substrates, all belonging to the kanamycin
class, making AAC-VIa one of the least promiscuous AGMEs. Kinetic parameters of the few
substrates of AAC-VIa showed variable rates (Table 2.1). Even highly similar aminoglycosides
showed surprising differences. For example, while kanamycin B was a substrate with a turnover
rate of 14.5 ± 0.6 s-1, there was no measurable turnover with kanamycin A. These two
aminoglycosides differ by OH versus NH2 at the C2’ site (Figure 2.5). Since these groups are
similar in size and both can be involved in hydrogen bond formation, it is not clear why
replacement of the amine functionality at this position (kanamycin B) with hydroxyl (kanamycin
A) causes this difference. It is known that the active sites of aminoglycoside modifying enzymes
have several negatively charged side chains. Thus, it is possible that positively charged C2’-amine
group may play a critical role in positioning the N3 site for catalysis.
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Table 2.1 Steady state kinetic parameters for AAC-VIa
Aminoglycoside

kcat (/s)

Km(µM)

kcat/Km (/M/s) x 106

Gentamicin C2

18.4 ± 0.6

3.0 ± 0.7

6.1

Gentamicin C1

9.7 ± 0.3

2.0 ± 0.4

4.7

Sisomicin

24.5 ± 0.8

15 ± 3.2

1.6

Tobramycin

43.5 ± 2.4

106 ± 20

0.4

Kanamycin B

14.5 ± 0.6

80.2 ± 16.3

0.2

Kanamycin A

<0.05

_

_

Ribostamycin

<0.07

_

_

Neomycin B

<0.025

_

_

Figure 2.5 Structures of aminoglycosides. Structures of kanamycins (left panel); kanamycin A
(top), kanamycin B (middle and tobramycin (bottom). Right panel shows gentamicin C1 (top),
gentamicin C2 (middle) and sisomicin (bottom). Single site differences are highlighted in bold.
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Optimal alignment or binding of kanamycin A may no longer be feasible due to loss of positive
charge at this site. There is also single site difference between tobramycin and kanamycin B; the
3’-OH of kanamycin B is -H in tobramycin, which resulted in a threefold increase in kcat without
affecting KM. Another structurally similar pair that showed different behavior was gentamicins C1
and C2. While gentamicin C2 yielded a kcat value of 18.4 ± 0.6 s-1, gentamicin C1, which differs
by a methyl substitution at N5 (Figure 2.5) showed an approximately twofold slower turnover rate.
It is likely that replacement of a proton with a methyl group at this site may create steric clash with
a side-chain and affect optimal alignment of the N3 site for catalysis. The highest kcat was observed
with tobramycin. Gentamicin C2, on the other hand, has the highest kcat/KM. Sisomicin has a
twofold lower turnover rate relative to tobramycin, but fourfold higher kcat/KM. No activity was
detected with neomycin group of aminoglycosides. It is likely that the active site of AAC-VIa is
unable to accommodate neomycins due to different substitution pattern at the 2-deoxystreptamine
ring (Figure 2.5).
In order to determine the most appropriate temperature for storage of the purified AAC-VIa,
activity assays were performed with enzymes stored at 4˚C, -20˚C and -80˚C (Table 2.2). By
comparing the relative activities of the enzyme stored at different temperature, 4°C was found to
be the most appropriate for the storage of AAC-VIa.
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Table 2.2 Activity assays to check the activity of enzyme stored at various temperatures
Enzyme storage

Activity (nmoles/min)

temperature (˚C)

Specific activity

kcat (s-1)

(µmoles/min/mg)

4

19.7

61.5

33.1

-20 (first thaw)

22.2

69.4

37.3

-20 (second thaw)

14.6

45.7

24.6

-80 (first thaw)

12.1

37.8

20.3

-80 (second thaw)

11.1

34.7

18.6

2.4.4 Characterization of AAC-VIa
Further characterization of purified AAC-VIa was performed by using CD spectroscopy and
differential scanning calorimetry (DSC). CD was performed to ascertain that the purified protein
was folded. By observing the characteristic absorbance of alpha helical structures of the protein at
222nm, it was evident that the protein was properly folded. Wavelength scans with AAC-VIa, in
the presence of ligands like tobramycin and sisomicin produced superposable curves with that of
the apoenzyme, indicating that no major structural changes happen upon ligand binding (Figure
2.6). Unfolding of the secondary structure of the enzyme was also followed by CD, both in the
presence and absence of ligands. Higher melting temperature was observed in the case of enzyme
bound with sisomicin, which binds more tightly to AAC-VIa as compared to tobramycin.
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Figure 2.6 Circular dichroism scans. Wavelength scans (A) and temperature scans (B) of apo
AAC-VIa (green), with tobramycin (blue) and sisomicin (purple) using CD spectroscopy.

To determine whether the unfolding of protein is reversible or not, DSC was performed. AACVIa’s thermal denaturation was observed to be irreversible. The apoenzyme showed a single peak,
this indicates a single step, two states unfolding event (Figure 2.7). In the presence of saturating
concentrations of ligands, the melting temperature (Tm) increased. This is expected because in the
case of enzyme-ligand complexes, the heat of unfolding includes the heat from the release of the
bound ligand from the enzyme as it unfolds. This is similar to what was observed in the CD
temperature scans, tighter binding ligands shift the Tm to a greater extent.
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Figure 2.7 Melting temperature determination by DSC. DSC scans of apo AAC-VIa (green),
and in presence of saturating concentrations of tobramycin (light blue), kanamycin B (purple) and
sisomicin (blue).

Table 2.3 Determination of melting temperatures by DSC
Sample
AAC-VIa
AAC-VIa + tobramycin
AAC-VIa + kanamycin B
AAC-VIa + sisomicin

Tm (°C)
43.7
46.7
47.6
55.3

2.5 Discussion
AAC-VIa is one of the least promiscuous aminoglycoside modifying enzymes, demonstrated by
its narrow substrate profile, limited to only 5 substrates. All of the AAC-VIa’s substrates are
restricted to the kanamycin class, which is in contrast to the more promiscuous aminoglycoside
modifying enzymes, which typically modify aminoglycosides from both the neomycin and
kanamycin classes.
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Unlike the more promiscuous AAC-IIIb, AAC-VIa is also able to distinguish between its
substrates kinetically. AAC-IIIb catalyzes all of its substrates at a comparable rate. AAC-VIa, on
the other hand, catalyzes gentamicin C2 twice as fast as gentamicin C1, the only difference
between the two being a methyl group at the 5’N position. Another distinction is observed between
kanamycin B and kanamycin A, which are different only at the 2’ position. Kanamycin B has a NH2 group instead of a -OH group for kanamycin A, which gives no measurable activity (Table
2.1). Another difference between AAC-IIIb and AAC-VIa is that AAC-IIIb’s catalytic efficiency
is at least 20 times that of AAC-VIa (for sisomicin, AAC-IIIb’s kcat/KM is 30.7 compared to AACVIa’s 1.6) [38]. This indicates that the AAC-VIa is a much slower enzyme compared to the more
promiscuous ones. Activity assays were performed with AAC-VIa stored at different conditions
to determine optimal storage conditions. It was found that the activity of the enzyme stored at 20˚C and -80˚C decreased to 70% and 60%, respectively, of the original activity upon the first
freeze-thaw cycle (Table 2.2). Thus, it was decided to store the enzyme at 4˚C. The activity of the
enzyme was also checked throughout the storage period and was found that the activity reduces
by about 50% by the end of 2 weeks. So, all subsequent experiments were performed with enzyme
while it still retained greater than 90% activity. In contrast to AAC-VIa, the other more
promiscuous acetyltransferase, AAC-IIIb, and phosphotransferase, APH (3’)-IIIa, can be frozen
without causing measurable decrease in the activity (unpublished data).
Further characterization of AAC-VIa was carried using CD and DSC. CD spectra obtained in the
presence and absence of ligands demonstrate that the tighter binding ligands cause a greater
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increase in Km as compared to the weaker binding ones. Additionally, DSC demonstrated that
thermal denaturation is irreversible for AAC-VIa, as is the case with most AGMEs, except APH
(3’)-IIIa (Dr. Ed Wright, unpublished data).
Thus, AAC-VIa exhibits quite different properties, which distinguish it from the more
promiscuous acetyltransferases. More detailed thermodynamic and structural characterization of
AAC-VIa will be undertaken as described in the subsequent chapters.
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CHAPTER III
THERMODYNAMICS OF AN AMINOGLYCOSIDE MODIFYING ENZYME WITH
LOW SUBSTRATE PROMISCUITY: THE AMINOGLYCOSIDE N3
ACETYLTRANSFERASE -VIa
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A version of this chapter was originally published by Prashasti Kumar and Engin H. Serpersu in
Proteins: Structure, Function and Bioinformatics, 2017, 85(7): 1258-1265.
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3.1 Abstract
Thermodynamic, and structural properties of the aminoglycoside N3-acetyltransferase-VIa (AACVIa) are determined. Binding of aminoglycosides to AAC-VIa was enthalpically favored and
entropically disfavored with a net result of favorable Gibbs energy (ΔG< 0). A net deprotonation
of the enzyme, ligand, or both accompanied the formation of binary and ternary complexes. This
is opposite of what was observed with several other aminoglycoside N3-acetyltransferases, where
ligand binding causes more protonation. The change in heat capacity (ΔCp) was different in H2O
and D2O for the binary enzyme–sisomicin complex but remained the same in both solvents for the
ternary enzyme–CoASH–sisomicin complex. Unlike, most other aminoglycoside-modifying
enzymes, the values of ΔCp were within the expected range of protein-carbohydrate interactions.
Solution behavior of AAC-VIa was also different from the more promiscuous aminoglycoside N3acetyltransferases and showed a monomer-dimer equilibrium as detected by analytical
ultracentrifugation (AUC). Binding of ligands shifted the enzyme to monomeric state. Data also
showed that polar interactions were the most dominant factor in dimer formation. Overall,
thermodynamics of ligand-protein interactions and differences in protein behavior in solution
provide few clues on the limited substrate profile of this enzyme despite its >55% sequence
similarity to the highly promiscuous aminoglycoside N3-acetyltransferase.
3.2 Introduction
The aminoglycoside N3-acetyltransferase-VIa (AAC-VIa) is one of several acetyltransferases that
modify the N3 site of the 2-deoxystreptamine ring of aminoglycosides [58]. AAC-VIa is one of
the least promiscuous of the N3-acetyltransferases despite its >55% sequence similarity to highly
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promiscuous aminoglycoside N3-acetyltransferases[59]. To date, molecular basis of differences in
substrate promiscuity of these enzymes remains unknown. Even available crystal structures of
aminoglycoside-modifying enzymes with several different aminoglycosides fail to explain
significant differences in kinetic parameters of these aminoglycosides[42]. Thermodynamic
parameters of enzyme–ligand complexes of aminoglycoside N3-acetyltransferases are known only
for the highly promiscuous enzymes, the aminoglycoside N3-acetyltransferase-IIIb (AAC-IIIb),
and moderately promiscuous, the aminoglycoside N3-acetyltransferase-IIa (AAC-IIa) [55, 56, 60].
Thermodynamic data on several other, highly promiscuous, aminoglycoside modifying enzymes
that catalyze phosphorylation and nucleotidylation are also available [61-67]. However, there is
no thermodynamic data available for an aminoglycoside modifying enzyme with highly limited
substrate profile. Therefore, this work was undertaken to determine thermodynamics of ligand
binding to an aminoglycoside-modifying enzyme with low substrate promiscuity. This work
describes the thermodynamic characterization of AAC-VIa, an enzyme that can acetylate only five
aminoglycosides from kanamycins and gentamicins. Results described in this work show
differences in thermodynamic parameters and homodimerization between aminoglycoside N3acetyltransferases with high and low substrate promiscuity.
3.3 Materials and Methods
3.3.1 Analytical Ultracentrifugation (AUC)
Beckman XL-I analytical ultracentrifuge with An-50Ti rotor was used to perform the
sedimentation velocity experiments. Protein samples and the appropriate buffer reference were
loaded into the double-sector cells. Prior to the run, samples were allowed to equilibrate at room
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temperature for 1 hour. Sedimentation was performed at a speed of 50,000 rpm, 25˚C and
absorbance was recorded at 280 nm. SEDFIT (version 12.44) was used to fit the sedimentation
data to a continuous [c(s)] distribution model [68]. The partial specific volume of protein, buffer
density and buffer viscosity were calculated using SEDNTERP software (version 20110705) [69].
Study of concentration-dependent dimerization of AAC-VIa was performed in 50 mM Tris-Cl
(pH=7.6 at 25˚C), 100 mM NaCl. A protein concentration range of 5mM to 100mM was used. For
different concentrations of protein used, absorbance at different wavelengths was recorded. For
lower concentrations, 5 mM and 10 mM, absorbance at 230 nm was recorded in addition to 280
nm. For 20 mM, absorbance at only 280 nm was recorded. For concentrations higher than 20 mM,
254 nm and 280 nm was used. Binary and ternary enzyme–ligand complexes were studied in 50
mM MOPS (pH=7.6 at 25˚C), 100 mM NaCl solution.
3.3.2 Isothermal titration calorimetry (ITC)
Calorimetry experiments were performed using a VP-ITC microcalorimeter from Microcal, Inc.
(Northampton, MA). 10 mM AAC-VIa was used in all the titrations to ensure that >98% of the
enzyme was in monomeric state. All measurements were carried out in 50 mM PIPES/MOPS/Tris
(pH=7.6 at 25˚C) and 100 mM NaCl. Enzyme was extensively dialyzed against the appropriate
buffer and titrant solutions were prepared by diluting aminoglycosides into the final dialysate. The
formation of the ternary enzyme–CoASH–aminoglycoside complexes was followed by the
titration of enzyme–CoASH complex (>98% saturation with CoASH) with aminoglycosides.
Samples were degassed for 10 min before loading to the ITC chamber. The pH of the cell and
syringe solution was checked and adjusted to be within 0.03 pH units of each other.
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The catalytic activity of the enzyme was checked before and after the titrations and found to be
>85% in all cases. Nonlinear least-squares fitting of experimental data was performed using a
single-site binding model of the Origin software package (version 5.0) to determine the
thermodynamic parameters N (stoichiometry), KA (association constant) and ΔH (enthalpy
change). The Gibbs energy of binding (ΔG) and entropy change (TΔS) were calculated from the
equations ΔG = –RTlnKA and ΔG =ΔH – TΔS.
3.3.3 Homology modeling
Homology-based structure of AAC-VIa was determined as described earlier for AAC-IIIb [55].
Briefly, Molecular Operating Environment (MOE) was used to generate the homology model of
AAC-VIa. To choose an appropriate template for modeling, AAC-VIa amino acid sequence was
submitted to the protein data bank (PDB) search tool. The top search result was obtained to be
Bacillus subtilis protein YokD (PDB ID: 2NYG chain A). Homology models of both AAC-IIIb
and AAC-VIa have been built using the YokD protein as the template.
3.4 Results
3.4.1 Structure of AAC-VIa in solution
Previous studies showed that the highly promiscuous AAC-IIIb was a homodimer under all
conditions [55, 56]. In order to determine solution behavior of AAC-VIa, sedimentation velocity
experiments were performed by analytical ultracentrifugation (AUC). As shown in Figure 3.1,
AAC-VIa displays a monomer-dimer equilibrium in the absence of substrates. The dimer
formation was concentration dependent between 5μM and 100μM enzyme with more dimeric form
appearing at higher concentrations of the protein. Substrates affected the monomer- dimer
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equilibrium of AAC-VIa; in all cases, binding of aminoglycoside or CoASH or both shifted the
enzyme into monomeric form suggesting that the enzyme is active in the monomeric state (Fig.
3.2). The most significant effect was observed with the enzyme–CoASH complex. Increasing salt
concentration also shifted the equilibrium toward monomeric form of the apo-enzyme (Fig. 3.3)
indicative of the fact that polar interactions are the major contributors of dimer formation. This is
in contrast to the behavior of the highly promiscuous aminoglycoside nucleotidyltransferase (4’)
(ANT) where high salt shifts the equilibrium toward dimer formation [61, 62].

Figure 3.1 Concentration dependence of AAC-VIa’s monomer-dimer equilibrium.
Concentration of the enzyme was 5μM (green), 10μM (blue), 20 μM (orange) and 100μM
(magenta).
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Figure 3.2 Effect of ligand binding on the monomer-dimer equilibrium of AAC-VIa. Apoenzyme (20 μM, red), enzyme-CoASH (orange), enzyme-sisomicin (blue), and enzyme-CoASHsisomicin (dotted green).

Figure 3.3 Sedimentation coefficient of AAC-VIa (50μM) in different salt concentrations. No
added NaCl (red), 100 mM (green), and 500mM NaCl (blue).
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3.4.2 Thermodynamics of enzyme–aminoglycoside complexes
Thermodynamic parameters of the formation of enzyme–aminoglycoside complexes were studied
by isothermal titration calorimetry (ITC). Data from AUC experiments were used to determine the
appropriate conditions for ITC titrations where >98% of the enzyme was in monomeric state in all
experiments. With the exception of sisomicin, the binding affinities of other aminoglycosides as
well as CoASH were quite weak with low ΔH values and yielded results with large errors and,
therefore, only sisomicin was used for further studies. An example of typical titration pattern is
shown in Figure 3.4.

Figure 3.4 Representative ITC titrations of AAC-VIa. Titration using sisomicin (left) and
tobramycin (right) and as the ligand. Top panels represent thermograms and the bottom panels
represent isotherms.
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In general, binding of aminoglycosides to AAC-VIa is favored enthalpically and disfavored
entropically yielding an overall favorable ΔG. This is similar to what was observed with several
other aminoglycoside modifying enzymes where binding was enthalpically favored and
entropically disfavored [59]. The average enthalpy of binding was observed to be -8.6 ± 0.5
kcal/mol, with a stoichiometry of 0.95 and dissociation constant was determined to be 0.2μM.The
intrinsic enthalpy of the formation of enzyme–sisomicin complex was determined by performing
ITC titrations in several buffers with different heats of ionization. As described in detail earlier, a
plot of observed enthalpy (ΔHobs) versus the heat of ionization of buffers (ΔHion) yields a straight
line [70, 71].

Figure 3.5 Determination of intrinsic binding enthalpy and change in net protonation.
Intrinsic binding enthalpy upon formation of the binary complex of AAC-VIa with sisomicin ( )
and ternary complex of AAC-VIa-CoA and sisomicin ( ).Titrations were performed in 50mM
PIPES/MOPS/Tris, 100mM NaCl, pH=7.6. The values used for heat of ionization for PIPES,
MOPS, and Tris buffers are 2.76 kcal/mol, 5.22 kcal/mol, and 11.74 kcal/mol, respectively.
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The intercept on ΔHobs axis yields the intrinsic enthalpy and the slope of the line is the net
protonation (Δn) [64]. Data shown in Figure 3.5 yielded an intrinsic enthalpy (ΔHint) of -7.9 ± 0.9
kcal/mol for the binary enzyme–sisomicin and -8.9 ± 1.0 kcal/mol for the ternary enzyme–
CoASH–sisomicin complexes. The unexpected aspect of these results was that the negative slopes
observed for both complexes indicating that the formation of these complexes is accompanied by
net deprotonation of the enzyme, ligand or both. The net deprotonation, Δn, was -0.22 ± 0.1 and 0.32 ± 0.1 for the binary and ternary complexes, respectively. This is quite different than what was
observed with highly promiscuous aminoglycoside modifying enzymes where all titrations yielded
positive slopes in such plots indicating an overall net proton uptake [55, 56, 61, 62, 65-67]
The last thermodynamic parameter, the change in heat capacity (ΔCp), was determined from the
temperature dependence of the binding enthalpy. Solvent reorganization is one of the main
contributors to ΔCp [72] and earlier observations with several, highly promiscuous,
aminoglycoside modifying enzymes showed that solvent reorganization played an important role
in the formation of enzyme–aminoglycoside complexes [40, 59, 66, 67, 73-75] . Therefore, to
determine effects of solvent, binding experiments were performed in H2O and D2O. Figure 7 shows
the effect of temperature on binding of sisomicin to AAC-VIa in H2O and in D2O in the absence
and presence of CoASH. ΔHobs was more negative in H2O for the binary and ternary complexes.
However, while ΔCp remained constant for the ternary complex in H2O and D2O (Fig. 7; bottom
panel) (-0.50 ± 0.02 kcal mol-1 deg-1) it was more negative in H2O in the binary complex (Fig. 7;
top panel).

40

Figure 3.6 Heat capacity change. Heat capacity change of the binary AAC-VIa-sisomicin, (top)
and the ternary AAC-VIa-CoA-sisomicin (bottom) complexes in H2O ( ) and D2O ( ).

For the ternary complexes, the offset temperature, the temperature difference required to give
identical enthalpies in D2O and H2O, was 3.1˚C and ΔΔH (ΔHH2O – ΔHD2O) remained constant at
1.65 kcal/mol within this temperature range tested. Contrary to this, ΔΔH was temperature
dependent for the binary complex. It became more negative at higher temperatures and became
positive below 7.8˚C. Figure 3.7 highlights the difference between the binary and ternary
complexes as ΔΔH versus T plots.
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Figure 3.7 Temperature dependence of ΔΔH AAC-VIa-sisomicin binary complex ( ) and AACVIa-CoA and sisomicin ternary complex (----) ΔΔH values have been plotted against the
temperature. ΔΔH values were determined from the slopes of linear regression lines from plots of
ΔH vs. T (from Fig. 3.6).

3.5 Discussion
AAC-VIa is the enzyme with narrowest ligand profile among the enzymes that modify
aminoglycosides and have available detailed thermodynamic data. Kinetic, structural, and
thermodynamic data, described in this work, show differences between AAC-VIa and others.
AAC-VIa can catalyze acetylation of only a few substrates and with a range of catalytic rates and
efficiencies toward its substrates. For example, kanamycin A and kanamycin B, which differ only
at the 2’-site (-OH vs. -NH2) in their structure, are discriminated by the enzyme such that
kanamycin B is a substrate while no measurable activity was observed with kanamycin A.
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Replacement of the hydroxyl function at the 3’ of the kanamycin B by H in tobramycin increases
kcat by a factor of 3 without affecting KM. Similarly, the presence and absence of a methyl group
at the 5’N separates turnovers of gentamicin C1 and gentamicin C2 by a factor of 2. Such
differences yielded kcat/KM values that cover two orders of magnitude range. Similar
discrimination of structurally like aminoglycosides was also observed with AAC-IIa, which has a
broader substrate range with respect to AAC-VIa but still cannot acetylate structurally different
neomycins. Contrary to these, the highly promiscuous AAC-IIIb can acetylate kanamycins with
similar turnover rates [55, 56]. AAC-IIIb can also acetylate neomycins efficiently. These
observations suggest that the active site of AAC-VIa, unlike AAC-IIIb, is unable to adopt to bind
aminoglycosides with significant size and structural differences. Earlier studies with AAC-IIIb
suggested that a large loop over the aminoglycoside binding site is able to adopt different
conformations to render binding of a large number of aminoglycosides thermodynamically
favorable [39, 40, 75]. This loop is also present at the same length in AAC-VIa (Fig. 3.8).
The homology-driven structures of both enzymes align quite well (Fig. 3.8), except a small loop
that spans residues Y232 to G237 in AAC-VIa with corresponding residues of an unstructured
segment of residues G220-E223 in AAC-IIIb which is at the edge of the aminoglycoside binding
site (colored segments in Fig. 3.8). Thus either the large loops in both enzymes may have highly
different set of interactions affecting loop dynamics and conformation and/or the conformation
and dynamics of the bulge in the small loop of AAC-VIa has a significant effect such that AACVIa is unable to bind a number of ligands and position the N3 optimally for acetylation. Solution
studies with AAC-VIa and AAC-IIIb also highlighted another difference between these enzymes.
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Figure 3.8 Overlay of homology-derived structures of AAC-IIIb (274 amino acids) and AACVIa (299 amino acids). Structures overlay with a 1.7 angstrom RMSD which is impacted mainly
by the two loops near the aminoglycoside binding site. The large loop is the same length in both
enzymes and spans residues V78-A118 and D67-V106 in AAC-VIa and AAC-IIIb, respectively.
The small loop consists of residues Y232-G237 and G220-E223 in AAC-VIa and AAC-IIIb
respectively. Green segments are AAC-IIIb and pink are AAC-VIa. Ligand binding sites are also
shown.

Highly promiscuous AAC-IIIb is a homodimer under all solution conditions in the presence and
absence of ligands [76]. AAC-VIa, on the other hand, exists in monomer-dimer equilibrium and
the binding of ligands shifts the enzyme into monomeric state. Our earlier computation-and NMRbased work with AAC-IIIb showed that the loop was highly dynamic and its dynamic properties
were significantly altered by the binding of CoASH indicating that dimerization involves residues
away from the ligand binding site [39]. The distribution of polar residues in the back side of active
site in AAC-VIa was quite disperse and did not reveal any obvious patches that may be involved
in dimer formation. Furthermore, this enzyme is active in monomeric form and the dimer
formation may be result of fortuitous interactions in solution and may not be functionally relevant.
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Another aminoglycoside-modifying enzyme, the aminoglycoside nucleotidyltransferase (4’)
(ANT), also displays monomer-dimer equilibrium in solution. However, in that case, binding of
aminoglycosides to this enzyme shifts the equilibrium to dimeric form [61, 62].This enzyme is
also highly promiscuous and can modify kanamycins and neomycins. These observations suggest
that homodimeric forms of these enzymes may be better suited to be adopt their active sites for
binding of structurally diverse aminoglycosides, hence increased substrate promiscuity. Curiously,
the dimer formation is driven by hydrophobic interactions in the case of ANT [61] and polar
interactions drive the dimer formation with AAC-VIa. The presence of CoASH increases the
binding affinity of sisomicin to the enzyme. This is similar to observations with other
aminoglycoside N3-acetyltranferases. One of the thermodynamic parameters that is different from
others is the net protonation (Δn) accompanying the binding of ligands to AAC-VIa.
It is interesting to note that Δn has been always positive with the highly promiscuous
aminoglycoside-modifying enzymes indicating an overall proton uptake upon aminoglycoside
binding to the enzyme [55, 56, 61, 62, 65-67]. This property starts to change as the promiscuity of
the enzyme is reduced. Ternary enzyme–aminoglycoside–CoASH complexes of AAC-IIa yielded
negative Δn values indicative of a net proton release [60]. AAC-IIa can only modify kanamycins
and gentamicins but has broader substrate profile than AAC-VIa. The least promiscuous of these
three aminoglycoside acetyltransferases, AAC-VIa, has negative Δn for both, the binary and
ternary complexes. It remains to be seen whether this property is related to the differential substrate
promiscuity of these enzymes. The change in heat capacity (ΔCp) is negative for the binary and
ternary AAC-VIa–ligand complexes indicating that more hydrophobic surfaces are buried away
from the solvent in both H2O and D2O.
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However, while ΔCp remained the same in both solvents for the ternary AAC-VIa– sisomicin–
CoASH complex, it was more negative in H2O for the binary AAC-VIa–sisomicin. Differences in
ΔCp values indicate that contribution of solvation to binding enthalpy is temperature dependent in
the binary complex and remains the same in the ternary complex. These results suggest that once
CoASH is bound to the enzyme, the conformation of the protein is adopted such that the solvation
effects are similar in both solvents, which is not the case in the binary complex. This is highly
similar to what is observed with AAC-IIIb [40] Similarly, differential behavior of enzyme–ligand
complexes in H2O and in D2O has been observed with other aminoglycoside-modifying enzymes
suggesting that solvent effects play a significant role in the binding of ligands to aminoglycosidemodifying enzymes [40, 66, 67, 74, 75].
Thermodynamics of ligand-protein interactions and subunit-subunit interactions of the enzyme to
form homodimer in solution appear to be different for aminoglycoside-modifying enzymes with
high and low substrate promiscuity. It remains to be seen whether these properties are generally
applicable within the same family of enzymes.
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CHAPTER IV
A LOW BARRIER HYDROGEN BOND MEDIATES ANTIBIOTIC RESISTANCE IN A
NON-CANONICAL CATALYTIC TRIAD
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4.1 Abstract
One group of enzymes that confer resistance to aminoglycoside antibiotics through covalent
modification belongs to the GCN5-related N -acetyltransferase (GNAT) superfamily. We show
how a unique GNAT subfamily member uses a previously unidentified noncanonical catalytic
triad, consisting of a glutamic acid, a histidine, and the antibiotic substrate itself, which acts as a
nucleophile and attacks the acetyl donor molecule. Neutron diffraction studies allow for
unambiguous identification of a low-barrier hydrogen bond, predicted in canonical catalytic triads
to increase basicity of the histidine. This work highlights the role of this unique catalytic triad in
mediating antibiotic resistance while providing new insights into the design of the next generation
of aminoglycosides.
4.2 Introduction
Aminoglycoside antibiotics such as kanamycin, neomycin and tobramycin are common
bactericidal agents used to treat clinically important diseases caused by Gram–positive and Gram–
negative bacteria such as tuberculosis, meningitis, listeriosis and many nosocomial infections [77].
However, the efficacy of aminoglycoside antibiotics has been drastically reduced due to the
emergence of bacterial resistance [78].
Chemical modification is the most prevalent mechanism responsible for bacterial resistance to the
aminoglycoside antibiotics, which is achieved by aminoglycoside modifying enzymes (AGMEs)
[58]. AGMEs represent a mechanistically diverse family of enzymes that render aminoglycosides
ineffective through the transfer of various functional groups[78].
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Modification disrupts the requisite molecular interactions between the drug and its target, the
bacterial ribosome. The aminoglycoside acetyltransferases (AACs) were the first identified
members of the GCN5–related N–acetyltransferases (GNAT) superfamily of enzymes [44].
Enzymes belonging to the GNAT superfamily are universally distributed in nature and catalyze
the transfer of an acetyl group from acyl-CoAs to a primary amine group on diverse acyl–accepting
substrates

[29].

This

superfamily

includes

histone

acetyltransferases,

serotonin–N–

acetyltransferases, and glucosamine-6-phosphate N–acetyltransferases. Acetylation occurs
through a general mechanism involving the direct nucleophilic attack of the amine group to be
acetylated on the carbonyl carbon of the acetyl-CoA. Amongst the AACs, crystal structures of
several enzymes have been reported, yet details about the kinetic and catalytic mechanism are not
available for all of them [44, 47, 49]. Recently a unique structural fold was observed in a putative
GNAT acetyltransferase from Bacillus anthracis, BA2930 (PDB code 3E4F [79]). The crystal
structure of three additional members of this subfamily have also been reported, with all possessing
a similar fold, yet significant knowledge about catalytic mechanism is lacking for this
pathologically important GNAT subfamily [80].
Here we report on the aminoglycoside N3 acetyltransferase-VIa, AAC-VIa, a fifth member of this
GNAT subfamily, which was isolated from a resistant clinical strain of Enterobacter cloacae [41].
AAC-VIa transfers an acetyl group donated by acetyl-CoA to the N3 position on the unprimed ring
of the aminoglycoside. The X-ray and neutron crystal structures of AAC-VIa and its complexes
with reactants, allowed for the identification of a previously unidentified non–canonical catalytic
triad functioning to inactivate aminoglycoside antibiotics in this GNAT subfamily, in a mechanism
similar to the archetypal catalytic triad in proteases.
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Moreover, the neutron diffraction studies allowed for unambiguous identification of a low barrier
hydrogen bond, contentiously predicted to function in some proteases that utilize a conventional
catalytic triad. Direct visualization of the proton equidistant between the acceptor atoms, OE2 of
glutamic acid and the N1of histidine, was observed. Subsequent catalysis in the crystal was used
to capture the product of a catalytically–relevant ternary complex, resulting in a unique, postcatalysis conformational state of the acetylated sisomicin, while suggesting a potential mechanism
of product release. These studies allow for unprecedented chemical insights into this pathologically
relevant enzyme and protein superfamily, while suggesting the design requirements of the next
generation of aminoglycoside antibiotics.
4.3 Materials and Methods
4.3.1 Protein expression, purification and kinetic assays
Wild–type AAC-VIa used for crystallography was expressed and purified as previously described
[56, 81, 82]. The mutants were expressed similar to the wild–type enzyme and were purified in
their His tagged forms by using a Ni-Sepharose resin, followed by a MacroPrep Q column to
remove co-eluting proteins. Circular dichroism was used to confirm that proteins were folded
prior to kinetic analysis. Kinetic assays were carried out as previously described [56, 81, 82].
4.3.2 Crystallization and diffraction data collection
Crystals for X-ray diffraction were grown by hanging drop vapor diffusion in drops containing 2
μL of the protein solution mixed with 2 μL of the precipitant well solution. Sisomicin, CoASH,
ternary sisomicin/CoASH, and acetyl-CoA crystals were grown in 17–25 % PEG 4000, 0.2 M
ammonium acetate, 10 % glycerol, and 0.1 sodium citrate, pH 5.6 in the presence of 1 mM ligands.
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Crystals belonged to the P61 space group (Table 4.1). The crystals of the apo-enzyme were grown
from a precipitant solution containing 20–30% polyethylene glycol (PEG) 8000, 0.2 M MgCl2, 0.1
M Tris, pH 8.5. Crystals belonged to the C2 space group (Table 4.1). These crystals were
subsequently soaked in 1 mM acetyl-CoA and 1 mM sisomicin for 15 min to generate the
acetylated sisomicin product complex. This resulted in product crystals with a very high mosaicity
(2.5 degrees). Crystals were transferred to 35 % (wt/vol) PEG 8000 for cryoprotection, mounted
in a nylon loop, and flash frozen in liquid nitrogen. All X-ray diffraction data were collected at
100K on a Rigaku 007HFmicromax X–ray generator with a Raxis IV++ detector. The X-ray
diffraction data were scaled and indexed using HKL3000. The data collection statistics are listed
in Table 4.1.
Crystals for neutron diffraction were grown by sitting drop vapor diffusion in drops containing 15
μL of the protein solution mixed with 15 μL of the precipitant well solution. The apo- and
sisomicin–bound enzyme crystals were grown from a precipitant solution containing 20–30%
polyethylene glycol (PEG) 8000, 0.2 M MgCl2, 0.1 M Tris, pH 8.5, sisomicin, when present, was
added at a concentration of 1 mM. Crystals belonged to the C2 space group. Once the crystals
reached a volume of 0.4 mm3 (one month), the well solution was replaced with a D2O-containing
well solution to facilitate exchange of labile hydrogen atoms with deuterium over a three-week
time period. Crystals were then mounted in a quartz capillary for data collection at room
temperature by neutron diffraction (Table 4.2). Room temperature X-ray diffraction data was
collected on crystals grown and mounted in an identical manner (Table 4.2).
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Time–of–flight (TOF) neutron diffraction data were recorded using the MaNDi [83] instrument at
the Spallation Neutron Source (SNS) on site at ORNL using all neutrons between 2.0 and 4.0 Å
wavelengths. The crystal was static during data collection, whereas it was rotated on ω and φ
between images to increase coverage of reciprocal space. Diffraction images were processed and
integrated using the Mantid Package[84] and LAUENORM from the LAUEGEN Package [85].
LAUENORM performs a wavelength normalization of the Laue data and scaling between Laue
diffraction images.
4.3.3 Structure determination, model building and refinement
The initial structure was solved by molecular replacement using the Phaser program[86] with the
FrbF from Streptomyces rubellomurinus (3SMA) as a search model. Manual model building was
carried out in Coot [87] and refined using PHENIX[88]. The models exhibit good stereochemistry
as determined by MolProbity [89]; final refinement statistics are listed in Table 4.1. Atomic
coordinates and structure factors for the apo-enzyme, the binary complexes with CoASH, acetylCoA, sisomicin, the ternary AAC-VIa–CoASH–sisomicin complex and the binary complex with
the acetylated sisomicin have been deposited in the Protein Data Bank [90] under the accession
codes of 6BC6, 6BC5, 6BC4, 6BC7, 6BC3 and 6BC2, respectively. Atomic coordinates and
structure factors for the room temperature neutron and X–ray diffraction structures of apo– and
sisomicin bound AAC–VIa have been deposited in the Protein Data Bank under the accession
codes of 6BBR, 6BB2 respectively. All molecular graphics figures were prepared by PyMol (The
PyMOL Molecular Graphics System, Version 2.0 Schrödinger, LLC).
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4.4 Results
4.4.1 Crystal structure of AAC-VIa
In order to gain an understanding of the structure/function relationship of AAC-VIa mediated
antibiotic inactivation, the crystal structure of the enzyme, with and without bound substrates and
reaction products, was determined (Fig. 4.1). Crystallographic data are summarized in Tabl

Figure 4.1 Overall structure of apo acetyltransferase AAC-VIa. (A) Ribbon representation of
AAC-VIa with ordering of secondary structure elements indicated from N– to C–terminus. (B)
Surface representation of apo AAC-VIa. Two large cavities present in the apo AAC-VIa are
indicated by green and yellow surfaces.
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Table 4.1 Data collection refinement and statistics

Resolution
range

Space group
Unit cell
a, b, c (A)
β (°)

Apo

Sisomicin

CoA

Ternary

Acetyl CoA

Acetylated
sisomicin
50.0 to 2.2
(2.27 to 2.20)

50.0 to
2.2
(2.27 to
2.20)
C2

50.0 to 1.8
(1.86 to
1.80)

50.0 to 2.2
(2.28 to
2.20)

50.0 to 2.05
(2.12 to
2.05)

50.0 to 2.05
(2.12 to
2.05)

P61

P61

P61

P61

C2

89.0,86.
0 and
51.1
90,120
and 90

78.6,78.6
and 83.6
90,90 and
120

78.1,78.1
and 83.3
90,90 and
120

77.5,77.5
and 83.9
90,90 and
120

78.5,78.5
and 83.9
90,90 and
120

84.4,86.9 and
50.3
90,119.8 and
90

Unique
reflections
Multiplicity*

15393

26880

14077

18004

18240

14753

2.4(2.2)

2.9(2.8)

5.6(4.9)

2.9(2.7)

2.6(2.1)

3.0(2.6)

Completeness
(%)

90.5(94.
7)

98.7(96.3)

95.1(72.2)

99.3(98.2)

98.6(97.0)

91.8(97.3)

Mean
I/sigma(I)

8.8(2.4)

12.0(2.4)

23.0(3.8)

11.0(2.0)

11.6(2.3)

10.4(3.2)

Wilson Bfactor
R-merge

37.4

16.54

32.7

31.58

23.02

39.2

0.084
(0.504)

0.089
(0.532)

0.091
(0.484)

0.10
(0.602)

0.101
(0.526)

0.094
(0.554)

15388

26851

14073

17984

18233

14750

771

1302

688

899

905

737

0.236
(0.314)

0.149
(0.227)

0.176
(0.208)

0.189
(0.289)

0.179
(0.275)

0.282
(0.450)

0.267
(0.333)

0.186
(0.286)

0.212
(0.289)

0.207
(0.278)

0.205
(0.288)

0.308
(0.496)

Reflections
used
in refinement
Reflections
used for Rfree
R-work

R-free (%)
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Table 4.1 Continued
Apo

Sisomicin

CoA

Ternary

Acetyl
CoA

Acetylated
sisomicin

Number of
non-hydrogen
atoms
macromolecules
ligands
solvent
RMS(bonds)

2028
1
51
0.002

2089
35
398
0.009

2042
48
129
0.002

2048
79
185
0.002

2043
51
274
0.002

2028
35
57
0.004

RMS(angles)

0.5

0.9

0.6

0.5

0.5

0.9

Ramachandran
favored (%)
Ramachandran
allowed (%)
Ramachandran
outliers (%)
Clashscore

95.1

97.0

96.0

96.2

97.0

96.6

4.1

3.0

3.6

3.4

2.6

3.4

0.8

0.0

0.4

0.4

0.4

0.0

7

5

3

2

2

6

Average Bfactor
macromolecules

44

19

33

31

23

51

44

17

33

31

22

51

ligands

43

20

60

32

32

53

solvent
PDB Code

42
6BC6

30
6BC7

36
6BC5

34
6BC3

29
6BC4

49
6BC2

*Number in parentheses represent values in the highest resolution shell.

The fold of AAC-VIa places it in a distinct, non–canonical GNAT superfamily, with the overall
structure being essentially identical to the other four members whose structures are known to date,
YokD (PDB code 2NYG), FrbF (PDB code 3SMA[80]), HMB0038 (PDB code 5HT0) and
BA2930 (PDB code 3E4F[79]) (Fig. 4.2). A large L–shaped indentation is present on the surface
of AAC-VIa (Fig. 4.1). One arm of the indentation superimposes with the acetyl-CoA binding site

56

found in the FrbF molecular replacement search model, YokD and the BA2930 homolog, where
the donated acetyl group would be placed into the other intersecting cavity (Fig. 4.2).

Figure 4.2 Kinetics and homologs of AAC-VIa. (A) Steady state kinetics of AAC–VIa and the
three active site mutants. (B) Structural superimposition of closest AAC–VIa structural homologs
identified by the DALI server. (C) Sequence alignment of AAC–VIa structural homologs. The
active site catalytic triad in AAC-VIa is highlighted in magenta, antibiotic binding site residues in
green and acetyl–CoA binding residues in orange.
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Previous studies on AAC-VIa have shown that acetyl-CoA is utilized to modify several
aminoglycoside antibiotics, such as sisomicin, tobramycin and gentamicin [81]. The binary crystal
structures of acetyl-CoA, coenzyme A (CoASH) and sisomicin bound AAC-VIa were determined
(Table 4.1). In AAC-VIa, acetyl-CoA resides in a long groove on the protein surface that is mixed
with both polar and non–polar residues (Fig. 4.3A).
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Figure 4.3 Binary complexes of AAC-VIa. (A) Surface representation of AAC-VIa–sisomicin
(green carbon atoms) binary complex superimposed with the enzyme–acetyl-CoA (yellow carbon
atoms) binary complex. The AAC-VIa surface cavities that bind sisomicin and CoASH are colored
green and yellow respectively, whereas the catalytic triad is shown in magenta. (B) Close up view
of sisomicin (green carbon atoms) interaction with AAC-VIa. The site of antibiotic acetylation is
circled in red. (C) Close-up of view of acetyl-CoA (yellow carbon atoms) interaction with AACVIa. The acetyl donor is circled in red. Hydrogen bonds are represented as black dashed lines and
water molecules are shown as red spheres. The active site residues have carbon atoms colored
magenta.
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The acetyl-CoA binding site overlaps with the binding site identified in the AAC-VIa structural
homologs. The side chain of Arg48 is the only amino acid to undergo large conformational changes
upon binding of ligand. The pantetheine moiety of acetyl-CoA is bound through specific hydrogen
bonds at the base of the surface cavity, ultimately terminating with a hydrogen bond between the
donor acetyl carbonyl and the side chain of Thr186. A water molecule also hydrogen bonds to the
acetyl carbonyl and forms a hydrogen bonding network with two residues, His189 and Glu192,
which have been proposed in other studies to be important in the catalytic mechanism (Fig. 4.3)
[79, 80]. This water molecule is in the same location as the N3 amine of the sisomicin (Fig. 4.3C).
Interestingly, the side-chain of Glu192 is found in two conformations, one of which forms a short
hydrogen bond with His189, interacting in a manner similar to low barrier hydrogen bonds in
catalytic triads (Fig. 4.3). The interactions with CoASH are essentially identical to those found in
acetyl-CoA complex. The only exception is the shifting of the terminal thiol into a conformation
so that a hydrogen bonding network, similar to the terminal acetyl carbonyl, is formed with Thr186
and a water molecule (Fig. 4.4).
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Figure 4.4 The binary AAC-VIa–CoASH complex. Close–up view of CoASH (orange carbon
atoms) interaction with AAC-VIa. The CoASH is superimposed with the acetyl-CoA (yellow
carbon atoms) from the binary enzyme–acetyl-CoA structure. Hydrogen bonds are represented as
black dashed lines and water molecules are shown as red spheres. The active site resides have
carbon atoms colored magenta.

Sisomicin is located in the binding site that is directly adjacent to the acetyl-CoA binding pocket,
and bound by a network of polar and non–polar interactions (Fig. 4.3). One specifically bound
water molecule in particular (W4) is hydrogen bonded to the site of acetylation, the N3 position of
sisomicin on the deoxystreptamine ring, in addition to forming two hydrogen bonds with the
adjacent sisosamine ring and three to the protein. The N3 position of the central deoxystreptamine
ring is directly hydrogen bonded to N2 of His189, which is flanked on an -helix by Glu192 and
Thr186, the latter of which also hydrogen bonds to the acetyl group of the acetyl-CoA.
The local environment and hydrogen bonding interactions with the catalytically relevant functional
groups in the binary reactant structures are suggestive of a catalytic mechanism involving the
catalytic triad. Indeed, all of the features common to catalytic triads are appropriately positioned
in the AAC-VIa active site for catalysis.
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Glu192 hydrogen bonds to the N1 of His189, thereby making the N2 of His189 more basic. The
N2 of His189 is in direct hydrogen bonding geometry to be able to abstract a proton from the N3
position of the sisomicin, thus enabling formation of the nucleophile that would attack the acetylCoA. Moreover, the tetrahedral intermediate formed during the AAC-VIa-mediated acetylation
reaction, and the emerging oxyanion can be stabilized through hydrogen bonding to Thr186, in a
manner that mimics the oxyanion hole found in the archetypal catalytic triad of trypsin and other
serine proteases.
4.4.2 Neutron Diffraction reveals the presence of a low-barrier hydrogen bond
Room temperature neutron and X-ray diffraction data were collected on deuterium exchanged
crystals of the apo–enzyme and enzyme–sisomicin complex to directly visualize the protonation
state of the catalytic residues of this enzyme (Table 4.2). Figure 4.5 shows the nuclear diffraction
density of the sisomicin in the active site of AAC-VIa, where density for exchangeable deuterium
atoms is clearly visible as well as the interaction network of the catalytic triad.
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Table 4.2 Data refinement collection and statistics
Apo
Resolution range

X-ray
50.0-2.0
(2.07-2.00)

Neutron
15.0-2.3
(2.38-2.30)
I2

Sisomicin
X-ray
Neutron
50.0-1.9
15.0-20.0
(1.97-1.90)
(2.28-2.20)
I2

Space group
Unit cell
a, b,c (A)

51.6,86.1,78.8

51.6,86.1,78.8

β (°)

94.0

94.5

Unique reflections
Multiplicity*

22336
3.4(3.4)

14029
2.8(2.2)

25874
1.7(1.6)

15519
2.8(2.5)

Completeness (%)

97.4(95.3)

91.3(84.3)

99.3(97.2)

92.5(89.3)

Mean I/sigma(I)

11.5(3.1)

11.6(3.0)

17.2(3.1)

10.4(3.3)

R-merge

0.069(0.390)

0.154(0.287)

0.047(0.326)

0.147(0.360)

Reflections used
in refinement
Reflections used
for R-free
R-work (%)

22336

14029

25867

15512

1126

708

1286

763

15.9

22.1

15.0

19.8

R-free (%)

19

24.6

18.1

22.0

Number of nonhydrogen atoms
macromolecules
ligands
solvent
RMS(bonds)

2029
0
88
0.010

2055
31
126
0.013

RMS(angles)

0.934

0.81
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Table 4.2 Continued

Ramachandran
favored (%)
Ramachandran
allowed (%)
Ramachandran
outliers (%)
Clashscore
Average B-factor
macromolecules
ligands
solvent
PDB Code

Apo
97.0

Sisomicin
96.6

3.0

3.0

0.0

0.4

2.5

1.8

55.7

52.9
53.9
59.1
6BB2

58.2
6BBR

*Number in parentheses represent values in the highest resolution shell.
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Figure 4.5 Room temperature neutron structure of AAC-VIa. Close–up view of the neutron
diffraction model and nuclear density for sisomicin bound AAC-VIa. Sisomicin bound active site
residues are colored with magenta carbon atoms and sisomicin with green carbon atoms. His189
from the neutron diffraction data acquired with the apo-enzyme is shown and colored with tan
carbon atoms. The 2Fo–Fc nuclear density map is shown in light grey. The Fo–Fc deuterium
nuclear omit map for the proton involved in the LBHB is shown in green. Hydrogen bonds are
represented as red dashed lines.

A hydrogen bond is found between Glu192 and the N1 of His189, whereas the unprotonated N
of His189 hydrogen bonds to the proton to be abstracted from the neutral N3 of the sisomicin (Fig.
4.5). The distance between the Glu192 OE2 oxygen and the His189 N1 is 2.57 Å, which is an
uncharacteristically short hydrogen bond. The length of this hydrogen bond is on the order of bond
distances found in low barrier hydrogen bonds (LBHB), where the pKa of the donor and acceptor
moieties are equal, and the proton resides between the two atoms [91].
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The Fo–Fc nuclear density map, where the deuterium atom was omitted, was used to assign
position of this hydrogen atom (Fig. 4.5). Indeed, this atom is found 1.4 Å away from the N of
His189 and 1.2 Å from the Glu192 OE2, consistent with this being a LBHB. In the absence of
ligand, the distance between the Glu192 OE2 oxygen and the His189 N1 is 2.83 Å (Fig. 4.5). The
formation of the binary, sisomicin bound complex is likely the driving force for the difference in
the His189 conformation between the apo–enzyme and enzyme–sisomicin complex. Superposition
of the apo– and sisomicin–bound structures shows that the distance between the N of His189 and
the sisomicin amino proton is essentially identical (2.2 Å). The repositioning of the His189 side–
chain into a LBHB with Glu192 is likely not a steric effect, yet is due to the hydrogen bond formed
between the His189 N and the sisomicin lowering the N1 pKa or making the N1 more basic to
facilitate the LBHB with Glu192.
4.4.3 Kinetics and conservation of catalytic triad in homologs
In addition to conservation of many of the residues forming the acetyl-CoA binding site, in all
members of this GNAT subfamily with known structures, the suggested catalytically important
residues are conserved, including the oxyanion hole (Fig. 4.2).
Moreover, one highly promiscuous acetyl transferase, the aminoglycoside N3-acetyltransferaseIIIb (AAC-IIIb) [56, 82, 92] also show sequence conservation of the proposed catalytic residues
and binding sites identified in AAC-VIa (Fig. 4.2). To see the effect these residues have on AACVIa catalytic activity, activity assays of wild-type and mutants of Thr186, His189 and Glu192 were
carried out (Fig. 4.2). Indeed, mutating each of the individual residues proposed to be important
in the AAC-VIa catalytic mechanism decreases activity to 3-5% of the wild-type enzyme,
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suggesting the importance of these residues in this non–canonical catalytic triad. Furthermore, the
E192Q mutant demonstrates the importance of the strength of the LBHB in increasing the basicity
of the N2 of His189 in this catalytic mechanism.
4.4.4 Proposed Catalytic Mechanism
The structure of the noncatalytic, ternary enzyme–CoASH–sisomicin complex was solved to gain
further insights into catalytic mechanism (Table 4.1). The conformations of the bound sisomicin
and CoASH in the ternary complex overlap precisely with the conformations observed in the
respective binary enzyme–ligand complexes with the exception of the pantetheine tail of the
CoASH adopting a different conformation in the binary enzyme–CoASH complex, while adopting
the same conformation of the acetyl-CoA in the binary enzyme complex (Fig. 4.6).

Figure 4.6 Overlay of ternary enzyme–CoASH–sisomicin complex with binary complexes of
the enzyme with CoASH, acetyl-CoA, and sisomicin. The ligands of the ternary enzyme–
CoASH–sisomicin (orange/green carbon atoms) complex are found in the same conformation as
in the binary enzyme–sisomicin (dark grey carbon atoms) and enzyme–acetyl-CoA (yellow carbon
atoms) complexes. The pantetheine tail of the CoASH in the binary enzyme–CoASH (light grey
carbon atoms) is found in a different conformation than the CoASH in the binary and ternary
complexes.
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The co-localization of the CoASH in the ternary and the acetyl-CoA binary complexes suggests
this is the catalytically relevant conformation of the donor group. Therefore, a structural
superposition of the ternary enzyme–CoASH–sisomicin and the binary enzyme–acetyl-CoA
complexes is used to contextualize the catalytic mechanism (Fig. 4.7).
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Figure 4.7 Proposed AAC-VIa mechanism. (A) Proposed catalytic mechanism of AAC-VIa
mediated acetylation of sisomicin. (B) Close up view of active site of the ternary enzyme–
CoASH–sisomicin complex superimposed with the binary enzyme–acetyl-CoA complex. Active
site residues are colored with magenta carbon atoms, CoASH is colored with orange carbon atoms,
acetyl-CoA is colored with yellow carbon atoms and sisomicin with green carbon atoms. (C)
Close–up view of active site of the enzyme–acetyl–sisomicin complex superimposed with the
binary enzyme–acetyl-CoA complex. Active site residues are colored with magenta carbon atoms,
acetyl-CoA is colored with grey carbon atoms and acetylated sisomicin with green carbon atoms.
Hydrogen bonds are represented as red dashed lines.
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In this modelled catalytically competent ternary complex, Glu192 forms a low barrier hydrogen
bond to N1 of His189, thereby making the N2 more nucleophilic to abstract a proton from the N3
position of the sisomicin (Fig. 4.7). This hydrogen bonding network completes the catalytic triad
and generates the nucleophilic nitrogen on the antibiotic. The N3 on sisomicin is positioned in such
a manner (2.1 Å distance between atoms) that a direct in–line attack to the carbonyl carbon of
acetyl-CoA is possible (Fig. 4.7). Nucleophilic attack on the acetyl-CoA generates a tetrahedral
intermediate containing a negative charge on the oxygen atom, with the stabilization of the
negative charge being achieved through the hydrogen bond to Thr186 (Fig. 4.7). Collapse of the
tetrahedral intermediate, and abstraction of the proton from the doubly protonated His189,
generates the acetylated antibiotic and CoASH, while restoring the protonation state of the active
site in our model based on these structural studies (Fig. 4.7).
4.4.5 Product Release
Catalysis in the crystal was used to capture the product of a catalytically–relevant ternary complex,
resulting in a unique conformational state of the acetylated sisomicin post catalysis, while
suggesting a potential mechanism of product release (Table 4.1). Soaking of the crystals of the
binary enzyme–sisomicin complex in acetyl-CoA resulted in the formation of the acetylated
sisomicin product, whereas no bound acetyl-CoA or CoASH was observed. The localization of
atoms in the modelled catalytically competent ternary complex would place the methyl group of
the acetyl-CoA in a trans conformation (Fig. 4.7).
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However, when the tetrahedral intermediate collapses to the planar amide bond in the product
crystal structure, the acetyl group which is now on the antibiotic rotates to a cis conformation
placing the methyl group on the apolar side of sisomicin and the carbonyl on the polar side (Fig.
4.7). The planarization of the tetrahedral intermediate breaks the hydrogen bond formed with the
acetyl carbonyl and Thr186, while likely contributing to a higher energy product complex and
aiding in acetylated sisomicin release. Concomitant with the rotation of the acetyl group, the
conformation of the sisoamine ring flips from a chair conformation in the ternary complex to a
half-chair in the acetylated sisomicin product complex, potentially as a result of the formation of
the amide bond geometry and subsequent planarization (Fig. 4.8).

Figure 4.8 Product mediated cofactor release. Superposition of the acetylated sisomicin (grey
carbon atoms) structure in the binary enzyme–acetyl-sisomicin complex with the ternary enzyme–
CoASH–sisomicin (cyan protein carbon atoms, with sisomicin carbon atoms colored green and
CoASH carbon atoms colored orange) structure. The acetylation of sisomicin leads to flipping of
the adjacent sugar ring concomitant with active site rearrangement that would lead to loss of
CoASH product hydrogen bonds.
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The flipping of the ring has several effects that also likely lead to a product state with significantly
fewer bonding interactions than the starting reactant state. In the ternary complex, where sisomicin
is in a chair conformation, the N21 atom is placed into the binding site, forming a hydrogen bond
with Asp183, a residue conserved in the known structural homologs (Fig. 4.2). In the ternary
complex, this positions Asp183 so that it also hydrogen bonds to two water molecules, W1 and
W2, that also hydrogen bond to the acetyl-CoA. The N21 of sisomicin forms hydrogen bonds with
two water molecules in the ternary complex, W3 and W4, of which W4 also links to the acetylCoA. W4 has the potential to form five hydrogen bonds in the ternary complex. Three hydrogen
bonds can potentially be formed with the N21, N6 and O51 atoms on sisomicin, while one can also
be formed with the main chain of Asp183 and another with the side–chain of Asp239 (Fig. 4.8).
Upon acetylation, N21 no longer hydrogen bonds to W3, W4, or Asp183. The side–chain rotamer
of Asp183 changes as well, so that no hydrogen bonds are formed between W1 and W2. The
rotameric state of Asp239 also changes upon loss of a hydrogen bond with W4 (Fig. 4.8). The
acetylation–mediated flipping of the sisosamine antibiotic ring leads to the loss of all of these
hydrogen bonds and likely contributes to product release (Fig. 4.8). Indeed, the binary enzyme–
CoASH complex lacks waters W1–4 (Fig. 4.9A). Yet, waters W2–W4 and W1–W2 are found in
the binary enzyme–sisomicin (Fig. 4.9B) and enzyme–acetyl-CoA complexes, respectively (Fig.
4.9C).
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Figure 4.9 Sisomicin mediated ordering of acetyl-CoA binding site. (A) Superposition of the
structures of the binary enzyme–CoASH complex (grey carbon atoms) with the ternary enzyme–
CoASH–sisomicin complex (cyan protein carbon atoms, with sisomicin carbon atoms colored
green and CoASH carbon atoms colored orange). Substrate waters 1–4 are absent in the binary
complex. (B) Superposition of the enzyme–sisomicin (grey carbon atoms) structure with the
ternary enzyme–CoASH–sisomicin complex (cyan protein carbon atoms, with sisomicin carbon
atoms colored green and CoASH carbon atoms colored orange). Substrate waters 2–4 are present
in the binary complex. (C) Superposition of the enzyme–acetyl-CoA binary (grey carbon atoms)
structure with the ternary enzyme–CoASH–sisomicin complex (cyan protein carbon atoms, with
sisomicin carbon atoms colored green and CoASH carbon atoms colored orange) structure.
Substrate waters 1 and 2 are present in the binary complex.
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4.5 Conclusions
Overuse of antibiotics has led to a drastic increase in bacterial antibiotic resistance which has
evolved into a major global health crisis. Evolution has provided bacteria with multiple routes
enabling the covalent modification of antibiotics, rendering countless modern antibiotics
inadequate to properly control bacterial infections. Central to the design and bactericidal nature of
antimicrobial agents, is a complete understanding of the enzymatic mechanisms bacteria employ
to inactivate their targets.
Aminoglycoside acetyltransferases (AACs) are just one type of aminoglycoside modifying
enzymes, but are the most frequently found variant in clinical isolates[93]. The complete structure
and mechanistic details of catalysis are known only for a handful of AACs, and all characterized
thus far confer resistance against a broad spectrum of aminoglycosides. Our studies presented here
on AAC-VIa, one of the least promiscuous AGMEs, offer direct evidence of the catalytic
mechanism of this enzyme at an unprecedented, proton–level of detail. The sequence and structure
similarity of AAC-VIa to two other aminoglycoside N3-acetyltransferases with high (AAC-IIIb)
and moderate substrate promiscuity (AAC-IIa) suggests that this mechanism is shared in all
aminoglycoside N3-acetyltransferases [38, 56].
The catalytic triad is a ubiquitous, catalytic archetype, but there has been no report of a catalytic
triad or conservation of the active site residues amongst the GNAT family of acetyltransferases
studied so far[29]. Interestingly, arylamine N–acetyltransferases, which are not a part of the GNAT
family, catalyze the acetylation of arylamines and arylhydrazines using a catalytic triad of Cys–
His–Asp, also utilized by cysteine proteases [53].
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Structural homologs of AAC-VIa have been characterized and although not explicitly stated or
identified, all contain the residues found in the active site of AAC-VIa. We demonstrate that the
catalytic triad of AAC-VIa is a new and unique variation, where the substrate itself completes the
non-canonical catalytic triad. Substrates have been reported to assist in catalysis by several
different mechanisms, including general base catalysis, intermediate state stabilization and
orientation of water molecules[94]. Substrate assisted catalysis (SAC) has been observed in many
naturally occurring enzymes like Ras p21 [95], type II restriction endonucleases [96], lysozyme
[97] and several enzymes from the serine protease family like subtilisin [98] and trypsin [99].
Many proteases that utilize a catalytic triad are inactivated by irreversible covalent modification
of the active site nucleophile, leading to permanent inactivation of the protein [100]. However, in
AAC-VIa the nucleophile does not reside on the enzyme itself, which allows for further evasion
of the facile inactivation of a nucleophile that would occur when it is located on the protein.
Amongst the enzymes that employ a catalytic triad, the trypsin catalytic triad has been studied
extensively, with neutron diffraction studies unequivocally establishing the role of the catalytic
histidine and the protonated forms of active site residues during catalysis [101]. Another feature
observed in the serine protease catalytic mechanism is the presence of an LBHB [102]. Since first
being proposed in 1993 [103], the role of LBHBs in enzyme-mediated catalysis has been a highly
debated topic [104-106] . Yet the role of the LBHB in in serine proteases like chymotrypsin,
aspartate proteases like HIV–1 protease, along with other enzymes like citrate synthase and triose
phosphate isomerase has been well studied and characterized.
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The strength of the LBHB functions to lower the transition state energy required for intermediate
formation in these catalytic mechanisms [107].
To our knowledge, the presence of LBHBs has not been reported or postulated to play a role thus
far, in any of the studies on antibiotic modifying enzymes. In the case of AAC-VIa, LBHB
formation is observed when sisomicin binds and forms a hydrogen bond with N atom of His189.
This serves to increase the basic nature of the N1 atom of His 189, thereby facilitating abstraction
of the proton from the antibiotic and subsequent formation of a tetrahedral intermediate with
acetyl-CoA. This novel, previously unidentified mechanism of antibiotic inactivation further
demonstrates the role of LBHB in catalytic triad-mediated enzymatic catalysis, while outlining the
requirements for the next generation of aminoglycoside antibiotics that these enzymes attempt to
inactivate. Design of antibiotics which can form the requisite polar interactions with the ribosome,
while having sufficiently perturbed pKa values that permit the evasion of the non-canonical
catalytic triad, will be required. Overall, the level of understanding of the AAC-VIa reaction
mechanism afforded by neutron diffraction experiments demonstrates the functional importance
of a proton level of detail in elucidation of catalytic mechanisms.
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CHAPTER V
CONCLUSIONS AND FUTURE DIRECTIONS
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5.1 Conclusions
In this work, we undertook a detailed characterization of the enzyme AAC-VIa to be able to
determine the molecular basis of ligand selection by aminoglycoside acetyltransferases. Despite
structural similarities between this enzyme and other aminoglycoside acetyl transferases with high
substrate promiscuity, AAC-VIa has a very limited substrate profile. In this work, we demonstrated
that AAC-VIa exhibits quite different properties as compared to the more promiscuous AAC-IIIb,
despite catalyzing the same chemical reaction and using the same catalytic machinery to do so.
In accordance to the different substrate specificities of two acetyltransferases, it was interesting to
note that AAC-VIa enzyme can kinetically distinguish amongst its limited number of substrates
but the more promiscuous AAC-IIIb cannot. This might suggest that the more promiscuous AACIIIb probably appeared earlier than AAC-VIa. Evolutionarily speaking, enzymes with broad
specificity have been shown to precede the more specialized enzymes having limited specificity
[108]. This route of evolution has been proposed for enzymes that exhibit either substrate or
catalytic promiscuity and can perform a reaction different from what the enzyme evolved for. A
promiscuous activity of an enzyme usually serves as the starting point in the divergence of new
functions within enzyme families and superfamilies. To describe the different substrate profiles
exhibited by enzymes like AACs, terms like broad specificity and substrate promiscuity have been
used, although those two terms cannot always be used interchangeably [32]. However, enzymes
having broad specificity have been shown to share some features with the classically promiscuous
enzymes, like large active sites, or having different subsites within the same active site and
conformational diversity.
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Another difference between AAC-VIa and AAC-IIIb was observed with respect to their oligomeric
state. AAC-VIa was demonstrated to exist in a monomer-dimer equilibrium, with more dimeric
form of enzyme appearing as concentration of enzyme is increased. Binding of ligands makes the
enzyme assume a more monomeric conformation. The other highly promiscuous enzymes like
AAC-IIIb [76] and ANT(4’) [61] have been reported to be homodimers, suggesting that having a
higher oligomeric state may render the enzyme to accept a wider range of substrates.
Thermodynamic characterization of AAC-VIa revealed a thermodynamic profile different than the
other acetyltransferases studied. In case of AAC-IIIb, presence of CoA increases the affinity for
binding of aminoglycosides to as much as 15-fold in certain cases [82]. However, for AAC-VIa,
the difference in binding affinity of the aminoglycoside for ternary complex vs. binary complex is
not significantly different. The dissociation constant for sisomicin binding to the enzyme is 0.2µM,
which changes to 0.1μM in the case of a ternary complex. Also, the enthalpy of the ternary complex
formation is only slightly higher than the formation of binary complex.
Ligand binding induces a change in pKa’s of functional groups of the enzyme and/or ligand. This
results in AAC-IIIb displaying a net protonation (Δn>0) on the formation of binary and ternary
complexes. In contrast, for AAC-VIa, the opposite effect is observed. AAC-VIa undergoes net
deprotonation (Δn<0) upon formation of binary and ternary complexes with ligands. This implies
that substrate binding is accompanied by increases in pKa’s of ionizable groups.
Studies in D2O and H2O were carried out to determine the role of solvent in ligand binding by
AAC-VIa. Heat capacity changes were found to be solvent dependent in the case of binary complex
formation, but not for the ternary complex.
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Comparison of the observed enthalpy of binding between H2O and D2O allows us to determine
contribution of solvation changes to binding enthalpy.
According to Chervenak and Toone, the observed enthalpy of binding, ΔHs is the sum of the
intrinsic enthalpy of binding (ΔHint), which is not solvent related and the enthalpy arising from
solvent reorganization as a result of binding, ΔHs [72].The difference between the enthalpies in
two different solvents, ΔΔH= ΔHH2O-ΔHD2O),would represent the solvent reorganization since the
substitution of H2O to D2O does not affect the ΔHint. Thus, the term ΔΔH represents the
contribution of solvent reorganization to the binding enthalpy and is equivalent to ΔHs. The
hydrogen bonds in D2O are 10% stronger as compared to H2O and also the enthalpy of a hydrogen
bond in D2O is approximately 10% greater than in H2O [109-111]. Thus multiplying ΔΔH by a
factor of 10 and comparing it to the observed enthalpy of binding in H2O (equivalent to ΔHobs) can
determine the contribution of hydrogen bonds to solvent reorganization. If the two values are
similar, it indicates that the hydrogen bonding interactions are the major contributors to the
observed enthalpy of ligand binding. If the two values are not comparable, it suggests that other
interactions like electrostatic interactions, van der Waal’s forces, hydrophobic effects and
conformational changes also play a role, apart from just hydrogen bonding.
For AAC-VIa, ΔΔH stayed constant at -1.65kcal/mol in the case of AAC-VIa-CoASH-sisomicin
ternary complex formation, but was not the case for the AAC-VIa-sisomicin binary complex. So
the ΔΔH value for the ternary complex was multiplied by 10 and compared to the ΔHobs in H2O.
As observed in the table below (Table 5.1), the two values are dissimilar, thus indicating that
interactions other than just hydrogen bonding contribute towards the enthalpy of binding in the
case of ternary complex formation.
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Table 5.1 Comparison of 10(ΔΔH) to ΔHH2O for AAC-VIa-CoASH and sisomicin ternary
complex
Temperature (℃)

ΔΔH

10(ΔΔH)

ΔHH2O

(kcal/mol)

(kcal/mol)

(kcal/mol)

10

-1.65

-16.5

-3.6

15

-1.65

-16.5

-6.3

20

-1.65

-16.5

-9.0

25

-1.65

-16.5

-11.3

30

-1.65

-16.5

-13.7

35

-1.65

-16.5

-16.0

Further characterization of AAC-VIa through structural determination was highly successful and
yielded structures for all possible catalytically important complexes of an AGME for the first time.
Based on our crystal structures, we were also able to propose a novel catalytic mechanism,
involving a previously unidentified non canonical catalytic triad and a mechanism aided by a low
barrier hydrogen bond. Furthermore, these studies highlighted differences between catalytic
properties and solution structures of two acetyltransferases with high and low substrate
promiscuity.

This work provides insights into the working of a pathologically important

acetyltransferase, these observations will contribute in the design of next generation of
aminoglycoside antibiotics.
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5.2 Future directions
Further work on this project would entail obtaining crystal structures of AAC-VIa, complexed
with other ligands. As has been demonstrated previously, AAC-VIa catalyzes the acetylation of its
substrates with a range of fourfold difference in the turnover numbers. We specifically want to
focus on the ligands that bind weaker than sisomicin, namely tobramycin and kanamycin B to
determine if the differences in the kinetic rates of these substrates is a result of the enzyme’s
differential binding and interaction with them.
We have obtained diffracting crystals for the binary complexes of AAC-VIa with gentamicin,
tobramycin and kanamycin B and collected X-ray diffraction data. It has been observed earlier that
in the case of sisomicin, acetylation by AAC-VIa triggers conformational changes, causing
rearrangement of the active site, eventually aiding product release. The acetyl group, once
transferred to the antibiotic’s structure, rotates to a cis conformation. This is accompanied by
flipping of the sisoamine ring from a chair conformation to half-chair. This flipping causes the loss
of most of the hydrogen bonds, which are observed in the binary complexes when the two
substrates initially bind to the active site. This eventually leads to a product state having
significantly fewer interactions, which helps the CoA and the acetylated drug release from the
active site (Fig. 5.1A) Based on our preliminary refined structures, we observe that the tighter
binding ligands like gentamicin bind to AAC-VIa, in the same initial conformation as sisomicin
(Fig 5.1B). Interestingly, the weaker binding ligands like kanamycin B (Fig. 5.1 C) bind in a
different conformation, which resembles the product state conformation of the acetylated
sisomicin, which makes lesser number of interactions in the enzyme’s active site.
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Figure 5.1 Different orientations of the AAC-VIa ligands in the binding site. (A) Superposition
of the structures of the binary enzyme-sisomicin complex (green carbon atoms, sisomicin carbon
atoms colored in green) with the binary enzyme-acetylated sisomicin complex (grey carbon atoms,
acetylated sisomicin carbon atoms colored in grey). (B) Superposition of the structures of the
binary enzyme-sisomicin complex (green carbon atoms, sisomicin carbon atoms colored in green)
and binary enzyme-acetylated sisomicin complex (grey carbon atoms, acetylated sisomicin carbon
atoms colored in grey) with the binary enzyme-gentamicin complex (cyan carbon atoms,
gentamicin carbon atoms colored in cyan). (C) Superposition of the structures of the binary
enzyme-sisomicin complex (green carbon atoms, sisomicin carbon atoms colored in green) and
binary enzyme-acetylated sisomicin complex (grey carbon atoms, acetylated sisomicin carbon
atoms colored in grey) with the binary enzyme-kanamycin B complex (magenta carbon atoms,
kanamycin B carbon atoms colored in magenta).
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The differences in the conformation of these substrates could possibly explain why AAC-VIa
prefers ligands like sisomicin and gentamicin over tobramycin and kanamycin B. We would also
be interested in determining the structures of the acetylated ligands for gentamicin, tobramycin
and kanamycin B, bound to AAC-VIa. It would be interesting to see how the conformations of
the aminoglycosides changes upon acetylation and how it compares to what has been previously
reported in the case of acetylated sisomicin. We are still in the process of obtaining the product
complexes and refining the data for these binary complexes. Alongside determination of the crystal
structures for the other ligand complexes of AAC-VIa, we are also planning to perform
computational studies to determine the energy of the low barrier hydrogen bond, observed in the
AAC-VIa-sisomicin complex.
It would also be helpful to determine the crystal structures of the more promiscuous
acetyltransferase, AAC-IIIb. AAC-IIIb shares a high sequence similarity (52%) with AAC-VIa,
yet they have quite different kinetic, and thermodynamic properties and behavior in solution.
AAC-IIIb is also a part of the same GNAT subfamily that AAC-VIa belongs to and shares the
same structural fold and active site residues.
So, the next step would be to solve the crystal structure of AAC-IIIb, in both the apoenzyme as
well as the ligand complexed forms. For the ligands, we would want to determine the structure of
both binary and ternary complexes, preferably using ligands from the neomycin as well as the
kanamycin class of aminoglycosides. Also, we would want to solve the structure of AAC-IIIb
bound to paromomycin and compare it to the neomycin bound structure. Based on previous data,
binary complexes of AAC-IIIb with neomycin and paromomycin display quite distinct
thermodynamic and dynamic properties as determined by ITC and NMR, respectively [40]. Even
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though both aminoglycosides belong to the neomycin class and are identical to each other except
for a different substitution at the 6’ position (amine in neomycin compared to a hydroxyl in
paromomycin), they exhibit opposite signs of change in the heat capacity (ΔCp) upon binding to
AAC-IIIb. HSQC spectra acquired with these different binary complexes shows that there are
ligand-dependent changes in the chemical environment of some backbone amides. Comparison of
the crystal structures of AAC-IIIb bound to neomycin and paromomycin would help us determine
the differential interactions between the enzyme and the ligands and also gain more information
about the specific residues involved.
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